This review evaluates the benefits and risks associated with prostate-specific antigen (PSA) screening for prostate cancer. Evidence indicates that PSA screening may reduce prostate cancer-specific mortality, but it also carries significant risks, including overdiagnosis and overtreatment. The review recommends that clinicians engage in shared decision-making with average-risk men aged 55
